Sterling Pharma will boost its API manufacturing capabilities

| By | API, CDMO, Drug Manufacturing

Contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions is investing £6 million (approximately 6,86 million) into its pilot plant facility at its UK site to enhance its scale-up and small to midscale commercial API manufacturing capabilities.

The expansion will increase the pilot plant’s capacity by 33% and enhance the site’s production capabilities and flexibility for small to mid-scale batch production. The investment will add three new reactor trains at scales of 225L, 500L and 1,360L to the cGMP facility. This will help to meet growing market demand for API batch sizes in the 10-100kg range and will complement the CDMO’s API full service offering and current scale-up capabilities from grams to tonnes.

As part of the investment the company’s site in Dudley, North East England, will also add a range of new capabilities to expand the ability to handle potent compounds across a range of equipment scales.

The expansion follows an investment in 2017 into the site’s milling, micronisation and solid form facility. Both investments form part of a strategic development plan totalling almost 14 million. The facilities are expected to be operational by mid-2018.

Established in 1969, Sterling’s site has a strong heritage in API services and a successful track record of compliance with both the MHRA and FDA. The company, which specialises in handling hazardous products, is now the UK’s largest provider of API development and manufacturing services to the pharmaceutical industry.